[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN114728966A - 作为mnk抑制剂的吡咯并三嗪类化合物 - Google Patents

作为mnk抑制剂的吡咯并三嗪类化合物 Download PDF

Info

Publication number
CN114728966A
CN114728966A CN202080080586.0A CN202080080586A CN114728966A CN 114728966 A CN114728966 A CN 114728966A CN 202080080586 A CN202080080586 A CN 202080080586A CN 114728966 A CN114728966 A CN 114728966A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
reaction
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080080586.0A
Other languages
English (en)
Other versions
CN114728966B (zh
Inventor
吴凌云
魏霞蔚
杨鹏
赵乐乐
张臣
姜宁
郑维
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Jiabao Pharmaceutical Silver Pharmaceutical Technology Co ltd
Original Assignee
Chengdu Jiabao Pharmaceutical Silver Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Jiabao Pharmaceutical Silver Pharmaceutical Technology Co ltd filed Critical Chengdu Jiabao Pharmaceutical Silver Pharmaceutical Technology Co ltd
Publication of CN114728966A publication Critical patent/CN114728966A/zh
Application granted granted Critical
Publication of CN114728966B publication Critical patent/CN114728966B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明公开了一类作为有丝分裂原激活的蛋白激酶作用激酶(MNK)抑制剂的吡咯并三嗪类化合物，以及它们在制备有丝分裂原激活的蛋白激酶作用激酶抑制剂药物中的应用，具体公开了式(I)所示化合物或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202080080586.0A 2019-11-18 2020-11-18 作为mnk抑制剂的吡咯并三嗪类化合物 Active CN114728966B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019111291145 2019-11-18
CN201911129114 2019-11-18
CN2020103299646 2020-04-24
CN202010329964 2020-04-24
PCT/CN2020/129603 WO2021098691A1 (zh) 2019-11-18 2020-11-18 作为mnk抑制剂的吡咯并三嗪类化合物

Publications (2)

Publication Number Publication Date
CN114728966A true CN114728966A (zh) 2022-07-08
CN114728966B CN114728966B (zh) 2023-08-18

Family

ID=75981354

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080080586.0A Active CN114728966B (zh) 2019-11-18 2020-11-18 作为mnk抑制剂的吡咯并三嗪类化合物

Country Status (11)

Country Link
US (1) US20220281895A1 (zh)
EP (1) EP4063364B1 (zh)
JP (1) JP7311207B2 (zh)
KR (1) KR20220101686A (zh)
CN (1) CN114728966B (zh)
AU (1) AU2020387982B2 (zh)
BR (1) BR112022009563A2 (zh)
CA (1) CA3158749A1 (zh)
MX (1) MX2022005951A (zh)
PT (1) PT4063364T (zh)
WO (1) WO2021098691A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023023189A2 (pt) * 2021-05-08 2024-01-30 Jumbo Drug Bank Co Ltd Composto, formas cristalinas a e b de um composto, método de preparação para a forma cristalina a de um composto, e, uso do composto, das formas cristalinas a e b e de formas cristalinas preparadas pelo método
WO2024017229A1 (zh) * 2022-07-19 2024-01-25 成都嘉葆药银医药科技有限公司 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087808A1 (en) * 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
CN106795162A (zh) * 2014-06-25 2017-05-31 效应治疗股份有限公司 Mnk抑制剂及其相关方法
WO2017117052A1 (en) * 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
WO2018218038A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US7405213B2 (en) * 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
WO2015091156A1 (en) * 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
NZ736852A (en) 2015-04-20 2024-07-26 Effector Therapeutics Inc Inhibitors of immune checkpoint modulators for use in treating cancer and infections
EA201891049A1 (ru) 2015-10-29 2018-10-31 Эффектор Терапьютикс, Инк. Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2
AU2016343980A1 (en) 2015-10-29 2018-06-07 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit Mnk1 and Mnk2
US20190388425A1 (en) * 2017-01-20 2019-12-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
TWI762579B (zh) 2017-02-14 2022-05-01 美商伊凡克特治療公司 六氫吡啶經取代之ＭｎＫ抑制劑及其相關方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795162A (zh) * 2014-06-25 2017-05-31 效应治疗股份有限公司 Mnk抑制剂及其相关方法
WO2017087808A1 (en) * 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
WO2017117052A1 (en) * 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
WO2018218038A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REICH,S.H.等: "Structure-based Design of Pyridone−Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition" *

Also Published As

Publication number Publication date
CA3158749A1 (en) 2021-05-27
JP2023502237A (ja) 2023-01-23
AU2020387982A1 (en) 2022-06-30
JP7311207B2 (ja) 2023-07-19
PT4063364T (pt) 2024-10-30
US20220281895A1 (en) 2022-09-08
EP4063364A4 (en) 2023-12-13
WO2021098691A1 (zh) 2021-05-27
BR112022009563A2 (pt) 2022-08-02
EP4063364B1 (en) 2024-09-25
MX2022005951A (es) 2022-07-27
AU2020387982B2 (en) 2023-08-03
CN114728966B (zh) 2023-08-18
EP4063364A1 (en) 2022-09-28
KR20220101686A (ko) 2022-07-19

Similar Documents

Publication Publication Date Title
CN113993860B (zh) 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物
CN113087704B (zh) 一种蛋白降解剂化合物的制备方法和应用
TWI768550B (zh) 作為dna-pk抑制劑的嘧啶并吡咯類螺環化合物及其衍生物
AU2021282122B2 (en) Fluoropyrrolopyridine compound and application thereof
WO2021110168A1 (zh) 作为erk抑制剂的螺环类化合物及其应用
WO2022188709A1 (zh) 噻吩类化合物及其应用
CN114761407B (zh) 作为高选择性ros1抑制剂的化合物及其应用
TW202317097A (zh) 戊二醯亞胺類化合物與其應用
CN114728966A (zh) 作为mnk抑制剂的吡咯并三嗪类化合物
WO2021204111A1 (zh) 作为dna-pk抑制剂的氨基嘧啶化合物及其衍生物
CN113825755B (zh) 作为irak4抑制剂的咪唑并吡啶类化合物
CN112574278A (zh) 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
TW202416976A (zh) 含六氫螺環［環丙烷—１，２＇—吡咯𠯤］的化合物
WO2022083687A1 (zh) 硒杂环类化合物及其应用
EA045188B1 (ru) Пирролотриазиновые соединения, действующие в качестве ингибитора mnk
EP3950688A1 (en) Nitrogen-containing spiro derivative as ret inhibitor
WO2021104470A1 (zh) 抗hbv的1,7-萘啶类化合物
EA046344B1 (ru) Соединение в качестве высокоселективного ингибитора ros1 и его применение
JP2024510647A (ja) オキサジアゾール置換スピロ環系化合物とその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant